Sunday (28.10.2018)

07:30 – 09:00

Room: Großer Saal

Scientific Session Interactive Case Discussion

  • Mark Hertzberg
  • Andrew Lister
  • Stage IV NLPHL

    • Dennis Eichenauer
  • Elderly cHL

    • Joanna Romejko-Jarosinska
  • HIV-positive HL

    • Otavio Baiocchi
  • Progress on anti-PD1 moAb

    • Sven Borchmann

09:15 – 10:15

Room: Großer Saal

Scientific Symposium (by Chugai Pharma) Oncology meets Autoimmunity

  • Andreas Engert
  • 09:15–09:45

    Autotransplant in systemic sclerosis

    • Jörg Henes
  • 09:45–10:15

    Autoimmunity in chronic GVHD

    • Daniel Wolff

10:30 – 12:00

Room: Großer Saal

Scientific Session Biology & Microenvironment

  • Christian Steidl
  • Anke van den Berg
  • 10:30–10:50

    Microenvironment

    • Ralf Küppers
  • 10:50–11:10

    Genotyping of cHL via Liquid Biopsy

    • Davide Rossi
  • Abstract Talk

    Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma patients to determine pathogenic mechanisms and monitor therapy

      Andreas Bräuninger
  • Abstract Talk

    Circulating Tumor DNA as a Biomarker for the Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma

      Ranjana Advani
  • Poster Pitch

    Functional analysis of CD30 in Hodgkin and anaplastic large cell lymphoma cell lines by CRISPR/Cas9-mediated gene knockout

      Annika Weiß
  • Poster Pitch

    Copy number aberrations in cell-free DNA of Hodgkin lymphoma

      Lieselot Buedts
  • Abstract Talk

    Clinical validation of an extracellular vesicle associated miRNA detection assay to monitor therapy response in classical Hodgkin lymphoma patients

      Esther Drees
  • Abstract Talk

    Molecular Mechanisms in the Pathogenesis of Composite Lymphomas

      Anna Lollies

12:15 – 13:45

Room: Großer Saal

Scientific Symposium (by Takeda Oncology) Tailoring sequencing and treatment targets

  • Peter Borchmann
  • 12:15–12:20

    Welcome and introduction

    • Peter Borchmann
  • 12:20–12:35

    Considering consolidation after autologous stem cell transplantation

    • Daniel Molin
  • 12:35–12:50

    Relapse after autologous transplant: options and optimising outcomes

    • Anna Sureda
  • 12:50–13:40

    Considering patient factors: challenging cases and clinical management

    • Peter Borchmann
    • Daniel Molin
    • Anna Sureda
  • 13:40–13:45

    Summary and close

    • Peter Borchmann

14:00 – 15:30

Room: Großer Saal

Scientific Session Early Stages

  • Richard Hoppe
  • John Raemaekers
  • 14:00–14:20

    Early-Stage Favorable HL: HD16

    • Andreas Engert
  • 14:20–14:40

    BREACH: Randomized Phase II Trial

    • Marc André
  • Abstract Talk

    Relapses in early PET-negative stage I/II Hodgkin Lymphoma (HL) after combined modality treatment or chemotherapy only in the EORTC/LYSA/FIL H10 trial

      Valeria Fiaccadori
  • Abstract Talk

    Maximum tumour dimension at baseline is associated with event-free survival in PET negative patients with stage IA/IIA Hodgkin lymphoma in the UK NCRI RAPID trial

      Tim Illidge
  • Poster Pitch

    Cardiovascular Radiation Dosimetry and Predicted Cardiovascular Risks from Involved Field Radiotherapy within the UK ‘RAPID’ Trial in Early Low-Risk Hodgkin Lymphoma

      David Cutter
  • Poster Pitch

    Quality Assurance of Involved-Node Radiotherapy: First Results of the HD17-Trial of the GHSG

      Jan Kriz
  • Abstract Talk

    Multicentric Italian Experience in Treatment of Nodular Lymphocyte Predominant Hodgkin lymphoma (NLPHL) in the Rituximab Era

      Manuel Gotti
  • Abstract Talk

    Brentuximab Vedotin and AVD Chemotherapy followed by Reduced Dose/Volume Radiotherapy in Patients with Early Stage, Unfavorable Hodgkin Lymphoma

      Joanna Yang

15:30 – 16:00

Room: Kleiner Saal

Main Program Poster Session

16:00 – 17:30

Room: Großer Saal

Scientific Symposium (by Bristol-Myers Squibb) Focus on cHL: Current Insights and Future Perspectives

  • Peter Borchmann
  • 16:00–16:05

    Welcome and Introductions

    • Peter Borchmann
  • 16:05–16:25

    The Evolving cHL Treatment Landscape

    • Graham Collins
  • 16:25–16:45

    Understanding the Unmet Need in cHL

    • Peter Borchmann
  • 16:45–17:05

    Focus on Biomarkers: Biology as a Key Driver of Therapeutic Benefit

    • Margaret Shipp
  • 17:05–17:25

    Panel Discussion

    • Peter Borchmann
    • Graham Collins
    • Margaret Shipp
  • 17:25–17:30

    Concluding Remarks

    • Peter Borchmann

17:45 – 19:15

Room: Großer Saal

Scientific Session Survivorship & Patients’ Perspective

  • Ananda Plate
  • Flora van Leeuwen
  • 17:45–18:05

    What Patients Really Want: The Global Lymphoma Patient Survey

    • Lorna Warwick
  • 18:05–18:25

    Cognitive Behavioral Therapy for Fatigue in HL

    • Hans Knoop
  • 18:25–18:45

    Genetic Susceptibility

    • Lindsay Morton
  • Abstract Talk

    Employment situation among long-term Hodgkin lymphoma survivors in Europe: An analysis of patients from nine consecutive EORTC-LYSA trials

      Maja Maraldo
  • Poster Pitch

    Early-Stage Hodgkin Lymphoma (HL) in the Modern Era: Harnessing Simulation Modeling to Delineate Long-Term Patient Outcomes

      Andrew Evens
  • Poster Pitch

    The reciprocal relation between cancer-related fatigue and physical and psychosocial functioning in survivors of Hodgkin lymphoma

      Nele Stadtbäumer
  • Abstract Talk

    Is routine laboratory testing useful in detecting relapse in patients with classic Hodgkin lymphoma in first remission?

      Ryan Lynch
  • Abstract Talk

    Contemporarily treated Hodgkin lymphoma patients have childbearing potential in line with matched comparators

      Ingrid Glimelius

ISHL11 Final Program

ISHL11 Final Program

ISHL11 Program at a glance

ISHL11 Program at a glance